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Inﬂuenza A viruses (IAVs) impact the public health and global economy by causing yearly epidemics and
occasional pandemics. Several anti-IAV drugs are available and many are in development. However, the
question remains which of these antiviral agents may allow activation of immune responses and protect
patients against co- and re-infections. To answer to this question, we analysed immuno-modulating
properties of the antivirals saliphenylhalamide (SaliPhe), SNS-032, obatoclax, and gemcitabine, and
found that only gemcitabine did not impair immune responses in infected cells. It also allowed activation
of innate immune responses in lipopolysaccharide (LPS)- and interferon alpha (IFNa)-stimulated mac-
rophages. Moreover, immuno-mediators produced by gemcitabine-treated IAV-infected macrophages
were able to prime immune responses in non-infected cells. Thus, we identiﬁed an antiviral agent which
might be beneﬁcial for treatment of patients with severe viral infections.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
IAVs mutate rapidly. Emerging viruses overcome the prevailing
immunity in the human population and cause global epidemics and
pandemics (Ferdinands et al., 2011). Antivirals remain an important
option for combating inﬂuenza outbreaks (Edinger et al., 2014;
Loregian et al., 2014; Muller et al., 2012).
The existing antiviral drugs and emerging antiviral agents
inhibit different steps of virus replication cycle (Fig. 1). For example,lar Medicine Finland, FIMM,
v).
B.V. This is an open access article umonoclonal antibodies that recognize the hemagglutinin (HA)
globular head, as well as compounds containing sialic acids inter-
ferewith attachment of IAV to host cells (Colpitts and Schang, 2014;
Nicol et al., 2012; Zanin et al., 2015). Inhibitors of cellular signalling
pathways attenuate virus endocytic uptake (Denisova et al., 2014).
Small molecules that interfere with endosomal acidiﬁcation and
viral M2 function, monoclonal antibodies which inhibit HA-
mediated fusion of viral and endosomal membranes, as well as
inhibitors of viral M1 degradation and ribonucleoprotein particle
(vRNP) uncoating block virus entry into host cells (Banerjee et al.,
2014; Cao et al., 2012; Denisova et al., 2012; Fujioka et al., 2011;
Muller et al., 2011; Wu et al., 2014). Small molecules directed to-
wards viral nucleoprotein (NP), the viral RNA-directed RNA poly-
merase (RdRP) complex (consisting of PB1, PB2 and PA) as well asnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Steps in the inﬂuenza virus replication cycle that are amenable to antiviral interventions. Inﬂuenza A virus (IAV) replication begins as the viral hemagglutinin (HA) binds to
sialic acid-containing cell-surface receptors (1) and the virus particle is engulfed by the host cell (2). The virus is transported in an endosome to the perinuclear cytoplasm. During
transportation, acidiﬁcation of the endosome triggers HA-mediated fusion of viral and endosomal membranes (3) and the release of viral ribonucleoprotein complexes (vRNPs) into
the perinuclear cytoplasm. The vRNPs, which contain the viral genetic information, migrate into the nucleus via nuclear pores (5). In the nucleus, the viral polymerase complex
transcribes the eight viral RNAs (6). The resulting viral mRNAs are transported into the cytoplasm and translated into 10e12 viral proteins (depending on the virus strain) (7).
Subsequently, eight of these proteins (including non-structural protein NS1) are transported to the nucleus (8). In the nucleus, NS1 inhibits transcription, as well as pre-mRNA
processing and mRNA nuclear export, whereas PB1, PB2, PA and NP replicate viral RNAs via complementary RNAs intermediates. Newly synthetized vRNPs leave the nucleus
and assemble at the plasma membrane to form new virus particles (9). The new virus particles bud from the cell and are released by a process that requires neuraminidase activity,
to infect other cells (10). Almost every step of the virus replication circle could be inhibited with antiviral agents. Examples of such agents are shown. UPS-ubiquitin proteasome
system, QC-quality control system.
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ways, or the DNA-directed RNA polymerase II and its regulators
inhibit vRNP nuclear import and transcription/replication of viral
RNA (Cianci et al., 2013; Clark et al., 2014; Furuta et al., 2009;
Ortigoza et al., 2012; Ortiz-Riano et al., 2014; Pautus et al., 2013;
Perwitasari et al., 2015; Smee et al., 2012). In addition, there are
dozens of small molecules that disturb translation of viral mRNA,
protein quality control, as well as maturation, trafﬁcking and as-
sembly of vRNPs (Chairat et al., 2013; Chase et al., 2008; Clark et al.,
2014; Das et al., 2013; Furuta et al., 2009; Gold et al., 2014; Lu et al.,
2015; Mata et al., 2011; Morita et al., 2013; Ortigoza et al., 2012;
Pautus et al., 2013; Perwitasari et al., 2014; Walkiewicz et al.,
2011; Zhang et al., 2012). There are also small molecules that
alter lipid metabolism and inhibit viral assembly and budding, as
well as inhibitors of viral neuraminidase (NA) which block virus
release from the cell surface (Chairat et al., 2013; Morita et al.,
2013).
Some of these agents are used as anti-IAV drugs in humans
(such as amantadine, rimantadine, arbidol, favipiravir, oseltamivir,
zanamivir, laninamivir, peramivir, and acetylsalicylic acid), whereas
others are in clinical development (such as DAS181, VX-787, riba-
virin and verdinexor) or in pre-clinical investigations (such as
CH65, C05, SaliPhe, nucleozin, geldanamycin, 17-AAG, LJ001, SA-19,
fattiviracin, TBHQ, 4C, gemcitabine, ASN2, bortezamib, carﬁlzomib,
C75, 25HC, SNS-032, MK2206) (Loregian et al., 2014; Muller et al.,
2012; Vanderlinden and Naesens, 2014). So far, only oseltamivirhas received a blockbuster status; however, oseltamivir-resistant
IAV strains emerge and reduce the efﬁcacy of the treatment
(Hurt, 2014; Muthuri et al., 2014). The question remains which
antiviral agents might be the most beneﬁcial for patients infected
with IAVs.
We hypothesised, that antiviral compounds, that efﬁciently
inhibit IAV replication with minimal impairment of host antiviral
responses, might be beneﬁcial for patients, because such thera-
peutics could allow development of innate and adaptive immune
responses, which would protect patients from virus co- and re-
infections. To test this hypothesis we established a model system
comprising human monocyte-derived macrophages and IAV virus
which lacks the capacity to antagonize antiviral responses. In this
study we used SaliPhe, SNS-032 and obatoclax, which inhibit IAV
entry in the cytoplasm, as well as gemcitabine, which attenuates
transcription and replication of viral RNA in the nucleus of infected
cells (Denisova et al., 2012; Perwitasari et al., 2015). Interestingly,
these compounds have been previously approved (gemcitabine) or
are in clinical (SNS-032, obatoclax) or pre-clinical (SaliPhe) devel-
opment for treatment of cancer or other diseases (Bajwa et al.,
2012; Gesto et al., 2012; Lebreton et al., 2008; Tong et al., 2010),
however, the antiviral effect of these agents in vitro could be ach-
ieved at much lower concentrations than that needed to mediate
cancer or normal cell death (Denisova et al., 2012).
We ﬁrst tested the effect of anticancer/antiviral SaliPhe, SNS-
032, obatoclax and gemcitabine on activation of immune
S. S€oderholm et al. / Antiviral Research 126 (2016) 69e80 71responses in the macrophages infected with mutant IAV strain. We
next studied the immuno-modulatory effect of these compounds in
LPS-, IFNa-, dsRNA-, and histamine-stimulated macrophages.
Finally, we analysed the effect of immuno-modulators produced by
IAV-infected compound-treated macrophages on immune re-
sponses in non-treated non-infected macrophages or lung epithe-
lial A549 cells. Our results suggested that treatment with
gemcitabine, but not with SaliPhe, SNS-032 or obatoclax, allowed
for the development of primary immune responses in IAV-infected
cells and secondary responses in non-infected cells. Thus, we
identiﬁed an antiviral/anticancer agent which could be further
developed for treatment of severe IAV infections. Furthermore, our
strategy can be exploited in different drug development pro-
grammes aiming to discover immuno-modulating properties or to
optimize side-effects of therapeutics.2. Materials and methods
2.1. Antiviral and non-infectious agents
Saliphenylhalamide (SaliPhe) was synthesized as described in
Lebreton et al. (2008). Obatoclax, gemcitabine and SNS-032 were
from Selleck Chemicals, USA. Compounds were dissolved in 100%
dimethyl sulfoxide (SigmaeAldrich) to obtain 10 mM stock solu-
tions. DsRNA molecules of 2948, 4063 and 6374 base pairs in size
were isolated from puriﬁed Pseudomonas phage phi6 nucleocapsids
as described (Romanovskaya et al., 2013). Lyophilised LPS from
Escherichia coliO55:B5was from Sigma Aldrich (St. Louis, MO, USA).
LPS was dissolved to 10 mg/ml in deionized water. Lyophilized IFNa
was from Biomed, Russia. IFNa was dissolved to 500 RU/ml in
deionized water. Histamine (SigmaAldrich, St. Louis, MO, USA) was
dissolved to 10 mg/ml in deionized water. All agents were stored
at 80 C.2.2. Cells and viruses
Human primarymacrophages were derived from leukocyte-rich
buffy coats from healthy blood donors (Finnish Red Cross Blood
Transfusion Service, Helsinki, Finland). Monocytes were isolated
and differentiated into macrophages as described previously
(Pirhonen et al., 1999). Monocytes were seeded in 96- or 6-well
plates and cultured in serum free macrophage media (Gibco) sup-
plemented with 10 ng/ml granulocyte macrophage colony stimu-
lating factor (GM-CSF; Biosource International) and 50 U/mL
penicillinestreptomycin (Lonza) at 37 C and 5% CO2 for 7 days,
polarizing the monocytes into macrophages of the acute pro-
inﬂammatory M1-phenotype. Before stimulation, the media was
replaced with fresh GM-CSF free macrophage media and macro-
phages were infected with IAVs or stimulated with LPS, dsRNA,
IFNa, or histamine.
Human inﬂuenza A/WSN/33(H1N1) viruses expressing wild
type (WSNWT) or R38A, K41A mutant NS1 (WSNRK/AA) were
generated using the WSN eight-plasmid-based reverse genetics
system in HEK293T and Vero cells as described previously
(Anastasina et al., 2015; Hoffmann et al., 2000). Human inﬂuenza A/
Udorn/307/1972(H3N2) (Udorn) was cultured in embryonated hen
eggs and the virus stock, with a titer of 256 hemagglutination U/ml,
was stored at 80 C. A virus dose of 2.56 hemagglutination U/ml
was used in the infection experiments unless stated otherwise. The
virus experiments were carried out under BSL-2 conditions and in
compliance with regulations of the University of Helsinki (permit
No 21/M/09). Viruses were titered in MDCK cells using a plaque
assay as described previously (Denisova et al., 2012, 2014).2.3. Cell viability assay
The compound efﬁcacy testing was performed in 96-well plates.
The compounds were added to the medium and 5 min later the
cells were infected with IAVs (moi 3) or stimulated with dsRNA,
LPS, IFNa, histamine or mock. The cell viability was analyzed with
the CellTiter -Glo assay (CTG; Promega) at 24 h post infection/
treatment/stimulation as described (Denisova et al., 2012). The
luminescence was read with a PHERAstar FS plate reader (BMG
Labtech). A sigmoidal dose-response curve was ﬁtted to the data
using SigmaPlot software. The effective concentrations that
enhanced the cell viability by 50% (EC50) and the cytotoxic con-
centrations that reduced cell growth by 50% (CC50), and selectivity
indexes were calculated from the sigmoidal functions as described
(Muller et al., 2011).
2.4. Immunoblotting
WSNWT-, WSNRK/AA- or mock-infected macrophages were lysed
in buffer containing kinase and phosphatase inhibitors. Protein
aliquots of whole-cell lysates (30 mg) were separated by electro-
phoresis in 10% SDS polyacrylamide gels. Proteins were transferred
onto Immobilon-P membranes, followed by blocking with 5% milk
in PBS (or 5% BSA in TBS for anti-phospho-protein antibodies).
Primary anti-phospho-IRF3 (Ser396; 4D4G; Cell Signaling), anti-
IkBa (44D4; Cell Signaling), guinea pig anti-NS1 (1:2000), rabbit
anti-NP (1:500), mouse anti-b-actin (1:5000; SigmaeAldrich) and
anti-GAPDH (Santa Cruz, sc-47724) antibodies were used, as
described previously (Anastasina et al., 2015; Kakkola et al., 2013;
Veckman et al., 2006). Secondary HRP-conjugated goat anti-
rabbit, rabbit anti-guinea pig or rabbit anti-mouse antibodies
(DakoCytomation, Carpinteria, CA, USA) were used in secondary
staining. Antibody binding was visualized by the ECL system on
HyperMax ﬁlms (GE Healthcare).
2.5. Phosphoprotein proﬁling
WSNWT-, WSNRK/AA- or mock-infected macrophages was
collected at 8 h post infection, cells were lysed and phosphorylation
proﬁles of 43 kinases and 2 kinase substrates were analyzed using
the human phosphokinase arrays according to the manufacturer's
instructions (R&D Systems).
2.6. Cytokine proﬁling
The medium from WSNWT-, WSNRK/AA- or mock-infected mac-
rophages was collected at 24 h post infection and clariﬁed by
centrifugation for 5 min at 14,000 rpm. Cytokines were analysed
using Proteome Proﬁler Human Cytokine Array panel A kit or
Proteome Proﬁler Human XL Cytokine Array Kit (R&D Systems)
according to manufacturer's recommendations. The results were
analysed using ImageJ software.
2.7. Enzyme-linked immunosorbent assay (ELISA)
Cytokine levels of TNFa and IFNl1 from macrophage culture
supernatants were analyzed using Ab pairs and standards from BD
Pharmingen (San Diego, CA, USA) and a VeriKine-DIY Human
Interferon Lambda ELISA kit supplied by PBL Interferon Source
(Piscataway, NJ, USA).
2.8. Gene expression proﬁling
RNA was extracted from WSNWT-, WSNRK/AA- or mock- infected
macrophages at 8 h post infection using RNeasy Plus mini kit
S. S€oderholm et al. / Antiviral Research 126 (2016) 69e8072
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previously (Anastasina et al., 2015). The data was deposited to the
GEO database (accession numbers: GSE66015 and GSE65699).
2.9. Reverse-transcription quantitative polymerase chain reaction
(RT-qPCR)
Quantitative PCR was performed on the Lightcycler 480 (Roche)
using Fast SYBR Green Master Mix (Roche) or TaqMan probes
(Denisova et al., 2014). The following sets of primers were used for
detection of speciﬁc genes or cDNA: IFNB1 (forward: 50-
GCCGCATTGACCACTATGA, reverse: 50-GCCAGGAGGTTCTCAACAA-
TAG), IFNA1 (forward: 50-ATGGCAACCAGTTCCAGAAG, reverse: 50-
CATCCCAAGCAGCAGATGAA), IFNA16 (forward: 50-GACTCACTTC-
TATAACCACCACAA, reverse: 50-TAGTGCCTGCACAGGTAAAC), NFKB1
(forward: 50-TGGAGGCCCTGAGACAAA, reverse 50-CCTGA-
GAGGTGGTCTTCACT), IFNG (forward: 50-AAACAGGGAAGCGAAAA,
reverse: 50-GCAGGCAGGACAACCAT), IL6 (forward: 50-TCAT-
CACTGGTCTTTTGG, reverse: 50-CTCTGGCTTGTTCCTCAC), CXCL1
(forward: 50- TGAGCATCGCTTAGGAGA, reverse: 50- AGGA-
CAGTGTGCAGGTAG), IL29 (forward: 50- AGGCTGAGCTGGCCCTGA,
reverse: 50- GGTGTGAAGGGGCTGGTC), IFNg (forward: 50-AAA-
CAGGGAAGCGAAAA, reverse: 50-GCAGGCAGGACAACCAT), and NS1
(forward: 50- GAAATGTCAMGAGACT, reverse: 50-
AGAAAGCTCTTATCTCTTG).
2.10. 35S protein labeling and autoradiography
Synthesis of viral and cellular proteins in infected macrophages
was monitored by incorporation of 35S-labeled methionine. Brieﬂy,
1 ml of 35S-labeled methionine (1200 Ci/mmol, 10 mCi/ml; Per-
kineElmer, USA) was added to 100 ml of cell culture media 30 min
before the cells were harvested. Cells were lysed and proteins were
resolved by SDS-PAGE. 35S-labeled proteins were visualized by ra-
dio autography using a Typhoon 9400 scanner (Amersham, USA).
3. Results
3.1. Human monocyte-derived macrophages and WSNRK/AA virus
represent an excellent model system for studying immuno-
modulatory effects of anti-IAV agents
In this study we utilized human monocyte-derived macro-
phages isolated from healthy individuals. These cells resemble
alveolar macrophages, which represent natural targets for IAV
(Anastasina et al., 2015; Short et al., 2012). As amodel virus we used
the inﬂuenza A/WSN/33(H1N1) variant (WSNRK/AA), which ex-
presses NS1 proteinwith R38A and K31Amutations (Fig. A1). These
mutations alter the NS1 ability to sequester viral RNA from recog-
nition by cellular pattern recognition receptors, which sense viral
RNA and trigger development of interferon responses (Donelan
et al., 2003; Min and Krug, 2006; Newby et al., 2007).Fig. 2. Characterisation of the model system for studying immune-modulating properties
(multiplicity of infection, moi 3), WSNRK/AA (moi 3) or mock, the cells were collected at 8 h af
their substrates were proﬁled using a phosphokinase array. The relative intensities of spots w
AA, log2Fc > 0.3 and<0.3). The heat map represents normalized expression data on the loga
panel A. The phosphorylation of IRF3 and integrity of IkBa were analysed at different time po
monitor virus replication. (C) Macrophages were infected as for panel A. Eight hours post in
proﬁling was carried out. A heat map of genes is shown (cut-off for WSNRK/AA, log2Fc > 4 and
compared to mock-infected cells. (D) Macrophages were infected as for panel A. Cells were c
antiviral and one housekeeping genes was analysed using RT-qPCRs. The points are mean va
the standard deviation (SD). (E) Macrophages were infected as for panel A, cell culture super
relative intensities of spots were calculated. A heat map of selected cytokines is shown (
expression data on the logarithmic scale as compared to mock-infected cells. (F) Cells were i
levels were determined by ELISA. The points are a mean values, the number of observationTo further characterize this system we analysed the effect of
WSNRK/AA infection on antiviral responses at transcriptional,
translational and post-translational levels. In particular, we infected
macrophages with WSNRK/AA, WSNWT or mock. After 8 h of infec-
tion we prepared cell lysates and analysed phosphorylation status
of interferon regulatory factor 3 (IRF3), heat shock protein 27
(HSP27), p38 mitogen-activated protein kinase (MAPK), c-Jun N-
terminal kinases (Jnk), protein kinase B (Akt), extracellular signal-
regulated kinases (ERK) and other phospho-proteins, which
modulate the expression of antiviral genes (Borgeling et al., 2014;
James et al., 2015; Jiang et al., 2015). We also analysed production
of viral NS1 protein and integrity of IkBa, which is an inhibitor of
nuclear factor kappa-light-chain-enhancer of activated B cells
(NFkB), which also plays a key role in activation of antiviral re-
sponses (Krug, 2015). Phosphoprotein proﬁling and Western blot
analysis revealed that WSNRK/AA infection enhanced phosphoryla-
tion of HSP27, p38, Jnk, Akt and ERK proteins in comparison with
WSNWT and mock infections (Fig. 2A and B, Fig. A1). These results
indicate that cellular MAPK, ERK, NFkB and IRF3 signalling cascades
are activated more strongly by WSNRK/AA, then by WSNWT
infections.
We also analysed the effect of WSNRK/AA infection on expression
of antiviral genes. For this, we infected macrophages with WSNRK/
AA, WSNWT or mock. After 8 h of infection we extracted total RNA
from the cells and proﬁled gene expression using microarrays and
qRT-PCRs (Fig. 2C and D). Infection with WSNRK/AA induced
expression of 93 genes over 8 fold, whereas infection with WSNWT
virus activated expression of only 57 genes over 8 fold. Interest-
ingly, 32 of these genes were induced in both WSNWT- and WSNRK/
AA-infected cells, however WSNRK/AA infection promoted stronger
expression of these genes. These results indicate that WSNRK/AA
virus was a better enhancer of transcription of antiviral genes in
human macrophages in comparison with the WSNWT virus.
We next analysed the effect of WSNRK/AA on the production of
cytokines in macrophages. In agreement with our transcriptomics
results, cytokine proﬁling and ELISA experiments revealed that the
secretion of cytokines was increased in WSNRK/AA-infected macro-
phages in comparison with WSNWT-infected cells (Fig. 2E and F,
Fig. A1). Altogether, these results suggest that human monocyte-
derived macrophages and WSNRK/AA virus could represent an
excellent model system for studying the effect of anti-IAV agents on
immune responses at transcriptional, translational and post-
translational levels.
3.2. Antiviral gemcitabine, but not SaliPhe, SNS-032, or obatoclax
allowed the activation of innate immune responses in human
macrophages infected with inﬂuenza WSNRK/AA virus
We utilized our model system to evaluate the effect of the
antiviral/anticancer SaliPhe, obatoclax, SNS-032 and gemcitabine
on the cellular antiviral responses. First, we assayed the effect of
these compounds on the viability of WSNRK/AA- and mock-infectedof anti-IAV agents. (A) Monocyte-derived macrophages were infected with WSNWT
ter infection and total cell lysates were prepared. Phosphorylation levels of kinases and
ere calculated. A heat map of selected phospho-proteins is shown (cut-off for WSNRK/
rithmic scale as compared to mock-infected cells. (B) Macrophages were infected as for
ints by Western blot. GAPDH was stained as a loading control. Viral NS1 was stained to
fection cells were collected, total RNA was isolated and genome-wide gene expression
<4). The heat map represents normalized expression data on the logarithmic scale as
ollected at 8 h after infection, total RNA was isolated, and the expression of four cellular
lues, the number of observations used to derive the values is 3 and error bars represent
natants were collected at 24 h post-infection, and cytokine levels were determined. The
cut-off for WSNRK/AA, log2Fc > 0.1 and <0.1). The heat map represents normalized
nfected as for panel A. After 24 h cell culture supernatants were collected, and cytokine
s used to derive the values is 3 and error bars represent the standard deviation.
Fig. 3. Effect of SaliPhe, SNS-032, obatoclax, and gemcitabine on transcription of antiviral genes and cytokine secretion in WSNRK/AA-infected macrophages. (A) Macrophages were
treated with 3 mM SaliPhe, 0.1 mM SNS-032, 2 mM obatoclax, 1 mM gemcitabine or remained non-treated, and infected with WSNRK/AA or mock. At 8 h after infection the cells were
collected, total RNAwas extracted and gene expression proﬁling was carried out. A heat map of selected genes is shown (cut-off for WSNRK/AA, log2Fc > 5 and <5). (B) Macrophages
were treated with different antiviral reagents and total RNA was isolated. The RNA was subjected to quantitative PCRs to detect IFNb1, TNFa and NS1 mRNA levels. The points are
mean values, the number of observations used to derive the values is 3 and error bars represent the standard deviation. (C) Macrophages were treated and infected as for panel B.
After 24 h cell culture supernatants were collected, and cytokine levels were determined. The relative intensities of spots were calculated. A heat map of selected cytokines is shown
(cut-off for WSNRK/AA, log2Fc > 0.1 and <0.1). (D) Macrophages were treated and infected as for panel B. At 8 h after infection cells were collected and the phosphorylation of IRF3
and expression of IkBa were analysed by Western blotting. GAPDH was stained to control equal sample loading. Viral NS1 was used to monitor virus replication.
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3 mM SaliPhe, 0.1 mM SNS-032, 2 mM obatoclax or 1 mM gemcitabine
remained viable after 24 h of infection (Fig. A2). Importantly, the
antiviral effect of these agents was independent on themacrophage
preparations and IAV subtype (Fig. A2).
Next, we evaluated the effect of antiviral agents on hosttranscriptional responses in WSNRK/AA- and mock-infected macro-
phages. We treated macrophages with selected concentrations of
these compounds and infected themwith WSNRK/AA or mock. Eight
hours post infection we proﬁled the expression of cellular genes
using microarrays (Fig. 3A). We found that SaliPhe, SNS-032 and
obatoclax suppressed the expression of dozens of antiviral genes
S. S€oderholm et al. / Antiviral Research 126 (2016) 69e80 75including CXCL10, IFNB1 and TNF. By contrast, gemcitabine treat-
ment did not attenuate and even enhanced the expression of some
of these genes including IFNB- and IFNA-family genes. RT-qPCR
analysis of IFNB1 and TNF, as well as viral NS1 (control) RNAs,
conﬁrmed our transcriptomics results (Fig. 3B). Thus, in contrast to
SaliPhe, SNS-032, and obatoclax treatments, treatment with gem-
citabine did not interfere with the transcription of cellular genes in
WSNRK/AA-infected human macrophages.
We next tested whether treatment with SaliPhe, SNS-032,
obatoclax or gemcitabine allowed production of cytokines by
WSNRK/AA-infected macrophages. In agreement with our tran-
scriptomics results, the cytokine proﬁling experiment revealed that
treatment with gemcitabine, but not SaliPhe, SNS-032, or obatoclax
allowed production of immuno-modulators by macrophages to
similar or even higher levels as compared to non-treated WSNRK/
AA- infected cells (Fig. 3C; Fig. A3).
We also tested whether the treatment with SaliPhe, SNS-032,
obatoclax or gemcitabine allowed the activation of antiviral sig-
nalling cascades in WSNRK/AA-infected macrophages. Western blot
analysis showed that IRF3 was phosphorylated and IkBa was
degraded in gemcitabine-, but not in SaliPhe-, SNS-032- or
obatoclax-treated WSNRK/AA-infected cells (Fig. 3D). These ﬁndings
are in agreement with our transcriptomics and cytokine proﬁling
results. Thus, we demonstrated that gemcitabine, but not SaliPhe,
SNS-032 or obatoclax, allowed development of efﬁcient antiviral
responses at transcriptional, translational and posttranslational
level in infected macrophages.
3.3. SaliPhe, SNS-032, obatoclax and gemcitabine allowed
activation of immune responses in macrophages stimulated with
LPS and IFNa, but not with dsRNA or histamine
Anti-inﬂuenza drugs are used mainly for treatment of severe
infections (Zambon, 2014) which are often associatedwith viral and
bacterial co-infections (Joseph et al., 2013). Therefore, we next
studied immuno-modulatory properties of SaliPhe, SNS-032, oba-
toclax and gemcitabine in human macrophages stimulated with
LPS, IFNa, dsRNA or histamine. DsRNA and LPS represent viral and
bacterial PAMPs, respectively, whereas IFNa and histamine are
immune-mediators which are produced by virus or bacteria-
infected cells (Figs. 2C and 3B) (Graham et al., 2015; Katze et al.,
2002; Matsumoto and Seya, 2008; Miller et al., 2005; O'Mahony
et al., 2011; Randall and Goodbourn, 2008; Sadler and Williams,
2008). For this, we ﬁrst analysed toxicity of dsRNA, LPS, IFNa and
histamine for macrophages (Fig. 4A). We found that 1 mg/ml dsRNA,
1 mg/ml LPS, 1 U/ml IFNa and 1 mg/ml histamine were not toxic for
the cells. We then treated macrophages with selected concentra-
tions of SaliPhe, SNS-032, obatoclax, gemcitabine, and stimulated
the cells with dsRNA, LPS, IFNa, or histamine. We measured the
transcriptional responses (Fig. 4BeE). We found that none of the
four antiviral agents affected transcriptional responses in LPS- or
IFNa-stimulated macrophages, whereas all four compounds
imbalanced the transcription in dsRNA- and histamine-stimulated
cells. Thus, our results indicate that different anti-IAV agents can
differentially affect immune responses under different stress
conditions.
3.4. Immune mediators produced by gemcitabine-, but not by
SaliPhe-, SNS-032-, or obatoclax-treated WSNRK/AA-infected
macrophages primed immune responses in non-infected cells
We next evaluated whether immune mediators produced by
compound-treated WSNRK/AA-infected macrophages can prime the
development of innate immune responses in non-treated, non-
infected cells. For this, we obtained media from WSNRK/AA- ormock-infected, compound-treated or non-treated macrophages
(M1). We diluted the media 1:20 and applied it to fresh macro-
phages (M2) from the same donor (Fig. 5A). After 8 h post treat-
ment we proﬁled the gene expression of M2 cells. We found that
the media from gemcitabine-treated WSNRK/AA-infected M1 mac-
rophages primed the transcription of antiviral genes in M2 cells to
the levels observed in macrophages treated with the media from
non-treated WSNRK/AA-infected M1 macrophages, whereas media
from SaliPhe-, SNS-032-, or obatoclax-treated WSNRK/AA-infected
M1 macrophages did not prime transcriptional responses in non-
infected M2 cells (Fig. 5B). Interestingly, IFN genes were strongly
up-regulated in virus-infected non-treated and gemcitabine-
treated M1 cells, but not in M2 cells stimulated with media from
corresponding M1 cells. RT-qPCR analysis of IFNB1 RNA conﬁrmed
our transcriptomics results, and RT-qPCR analysis of viral NS1
showed that there was no virus replication in M2 cells (Fig. 5C).
Next, we questioned whether M2 macrophages treated with
media from M1 cells produced cytokines. In agreement with our
transcriptomics results, cytokine proﬁling experiment revealed
that media from WSNRK/AA-infected gemcitabine-treated M1 mac-
rophages similarly to media from WSNRK/AA- infected non-treated
M1 cells triggered production of cytokines in M2 cells (Fig. 5D,
Fig. A4). By contrast, media from SaliPhe-, SNS-032-, or obatoclax-
treated M1 macrophages did not prime immune responses in non-
infected M2 cells. We also used media from M1 cells and applied it
to non-infected human lung epithelial A549 cells, and analysed the
produced cytokines after 24 h. We found that the media from
gemcitabine-treated virus-infected M1 macrophages, similarly to
media from non-treated virus-infected M1 macrophages, primed
the production of cytokines in A549 cells (Fig. A4). Media from
SaliPhe-, SNS-032-, or obatoclax- treated infected M1macrophages
was unable to trigger production of the cytokines. These results
suggest that treatment with gemcitabine, but not with SaliPhe,
SNS-032 or obatoclax, activated primary antiviral responses in
infected cells and secondary immune responses in non-infected
cells.
4. Discussion
In the present study we established a system for testing
immuno-modulating properties of drugs and drug candidates. We
utilized this system to demonstrate that gemcitabine, but not
SaliPhe, obatoclax or SNS-032 allowed the development of innate
immune responses in IAV-infected macrophages. Mechanistically,
treatment with gemcitabine, which targets cellular RNR and in-
hibits transcription and replication of vRNA, did not impair antiviral
cascades that could be initiated by cellular pattern recognition
molecules, such as TLR3, MDA5, and RIG-I upon recognition of viral
RNA. It also allowed activation of IRF3- and NFkB-pathways, which
cumulated in transcription and translation, as well as post-
translational modiﬁcations and secretion of immune mediators
from infected cells. Furthermore, gemcitabine did not interfere
with secondary immune responses in non-infected cells which
were triggered by immune-mediators produced by gemcitabine-
treated infected cells (Fig. 6). Moreover, gemcitabine was unable
to impair macrophage responses to other immune stimuli, such as
IFNa and LPS, which could be associated with viral and bacterial co-
infections and viral re-infections. Thus, gemcitabine treatment
limited viral replication and allowed development of immune re-
sponses in infected and non-infected cells, which could be neces-
sary for cell-mediated and humoral protection of patients with
severe inﬂuenza infections.
Our results pave the way towards further development of the
anticancer gemcitabine and its analogues as broad-spectrum anti-
viral agents. In particular, gemcitabine could be further developed
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Fig. 4. Effect of SaliPhe, SNS-032, obatoclax, and gemcitabine on cellular responses to different immune stimuli. (A) Macrophages were treated with increasing concentrations of
dsRNA, IFNa, LPS or histamine. After 24 h cell viability was measured by CTG and results were plotted. (BeE) Macrophages were treated with 3 mM SaliPhe, 0.1 mM SNS-032, 2 mM
obatoclax, 1 mM gemcitabine or remained non-treated and stimulated with 1 mg/ml dsRNA, 1 mg/ml LPS, 1 U/ml IFNa, 1 mg/ml histamine or remained non-stimulated. After 8 h, cells
were collected; total RNA was extracted and subjected to gene expression analysis. Heat maps of selected genes are shown (cut-offs: log2FcdsRNA> 2 and <2; log2FcLPS >5 and <-5;
log2FcIFNa> 2 and <2; log2FcHistamine >0.6 and <0.6).
Fig. 5. Immune responses of non-infected macrophages (M2) and A549 cells to immuno-modulators produced by IAV-infected, SaliPhe-, SNS-032-, obatoclax-, and gemcitabine
-treated macrophages (M1). (A) Schematics depicting experimental setup. Macrophages (M1) were treated with 3 mM SaliPhe, 0.1 mM SNS-032, 2 mM obatoclax, 1 mM gemcitabine or
remained non-treated, and infected with WSNRK/AA or mock. After 1 h the media were changed. After 12 h the media were collected and diluted 1:20 with fresh medium. The media
was applied to macrophages (M2) from the same donor or A549 cells. (B) M2 macrophages were stimulated as for panel A. After 8 h M2 cells were collected, total RNAwas extracted
and subjected to gene expression analysis. A heat map of differentially expressed M2 genes is shown (cut-off for WSNRK/AA, log2Fc > 4 and <4). (C) Total cellular RNA was analysed
also by quantitative PCRs to detect IFNB1 and NS1 mRNA levels. The points are mean values, the number of observations used to derive the values is 3 and error bars represent the
standard deviation. (D) M2 macrophages were stimulated as for panel A. After 24 h cell culture supernatants were collected, and cytokine protein levels were determined. The
relative intensities of spots were calculated. A heat map of differentially produced cytokines is shown (cut-off for WSNRK/AA, log2Fc > 0.1 and <0.1). (E) A549 cells were stimulated
as for panel A. After 24 h cell culture supernatants were collected, and cytokine protein levels were determined. The relative intensities of spots were calculated. A heat map of
cytokines produced by A549 cells stimulated with media from M1 macrophages is shown (log2Fc > 0.1 and <0.1).
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Fig. 6. Schematics showing effects of SaliPhe, SNS-032, obatoclax and gemcitabine on activation of innate immune responses in IAV-infected and non-infected cells. Upon IAV
infection of host cell viral ribonucleoprotein complexes (vRNPs) are released from virions into the perinuclear cytoplasm. Speciﬁc features on viral RNAs are recognised by cellular
pattern recognition receptors (PRRs). PRRs migrate to the nucleus where they mediate chromatin remodelling and activate transcription of antiviral genes. The transcripts are
translated on the ribosomes. Some of the translational products are cytokines which are secreted by the infected cells. These immuno-modulators activate immune responses in
non-infected cells. Gemcitabine, which inhibits transcription and replication of viral RNA, but not SaliPhe, SNS-032 or obatoclax, which block virus entry, allows activation of
immune responses in infected and non-infected cells.
S. S€oderholm et al. / Antiviral Research 126 (2016) 69e8078as anti-IAV, Sindbis virus, Semliki Forest virus, Echovirus 6, Herpes
Simplex virus-1, Human Immunodeﬁciency virus type 2, and Rift
Valley fever virus agent (Beach et al., 2014; Benedict et al., 2015;
Denisova et al., 2012). However, it should be noted that there are
some viruses, e.g. H5N1 viruses, which induce a cytokine storm
and, therefore, treatment with gemcitabine could harm infected
patients (Droebner et al., 2008). In this case, compounds that
inhibit cytokine expression (such as SaliPhe, SNS-032, or obatoclax)
may be useful for treatment of these viral infections. Thus,
immuno-modulatory properties of both virus and antiviral drugs
should be carefully considered for treatment of infectious disease.5. Conclusions
Here we developed a robust method for analysis of immuno-
modulating properties of available and prospective anti-inﬂuenza
agents. We utilized this method to demonstrate that gemcitabine
that targets transcription and replication of viral RNA, and notSaliPhe, SNS-032 and obatoclax, which inhibit IAV entry, allows
activation of primary antiviral responses in infected cells and sec-
ondary responses in non-infected cells. Gemcitabine and its ana-
logues might be beneﬁcial for treatment of patients with severe
seasonal IAV infections because treatment with such agents would
allow activation of immune responses and thereby could protect
patients against co- and re-infections. Thus, our study paves the
way towards further development of gemcitabine and its analogues
as antiviral drugs. Moreover, our strategy can be utilized in other
drug development programmes which aim to discover and exploit
immuno-modulating properties or to minimize side-effects of
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